



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Original article

Necrotizing pneumonia due to *Streptococcus pneumoniae* in children during the period of non-systematic use of PCV13 in Catalonia, Spain



Sebastià González-Peris^{a,*}, Magda Campins^{a,b}, Juan José García-García^{c,d,e}, Álvaro Díaz-Conradi^f, Ángela Domínguez^{c,g}, Pilar Ciruela^{c,h}, Mariona F. de Sevilla^{c,d,e}, Sergi Hernández^h, Carmen Muñoz-Almagro^{c,d,i}, Conchita Izquierdo^{c,h}, Gemma Codina^a, Sonia Uriona^{a,b}, Cristina Esteva^{c,d}, Anna Solé-Ribalta^d, Núria Soldevila^{c,g}, Ana María Planes^a, Johanna Martínez-Orsorio^d, Luis Salleras^{c,g}, Fernando Moraga-Llop^a, Barcino Working Group

^a Hospital Universitari Vall d'Hebron, Barcelona, Spain

^b Grup de Recerca en Epidemiologia i Salut Pública, Vall d'Hebron Institut de Recerca, Barcelona, Spain

^c CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

^d Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain

^e Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain

^f Hospital de Nens, Barcelona, Spain

^g Departament de Medicina, Universitat de Barcelona, Barcelona, Spain

^h Agència de Salut Pública de Catalunya, Barcelona, Spain

ⁱ Departament de Medicina, Universitat Internacional de Catalunya, Barcelona, Spain

ARTICLE INFO

Article history:

Received 18 May 2020

Accepted 15 August 2020

Keywords:

Necrotizing pneumonia
Pneumococcal pneumonia
Pneumococcal vaccines
Streptococcus pneumoniae

ABSTRACT

Background: Some studies have observed an increased incidence of necrotizing pneumonia (NP) in recent years. This might be related to the emergence of non-vaccine *S. pneumoniae* serotypes after PCV7 introduction although it is suggested that evolutionary factors may have modified the virulence and the interactions of pneumococci. The aim of this study was to clinically and microbiologically define NP in the population served by the three major paediatric hospitals in Barcelona (Catalonia, Spain).

Methods: A prospective observational study was conducted in patients <18 years hospitalized due to invasive pneumococcal disease (January 2012–June 2016). Data of confirmed cases of pneumococcal NP (diagnosed by culture or DNA detection and serotyped) were collected. PCV13 was not systematically administered in Catalonia during the study period, but was available in the private market so the vaccination coverage in children increased from 48.2% to 74.5%.

Results: 35 cases of NP were identified. 77.1% of cases were associated with empyema. In the first 4 years, a trend to a decrease in NP incidence was observed ($p=0.021$), especially in children <5 years ($p=0.006$). Serotype 3 was responsible for 48.6% of NP cases. Five patients with NP due to serotype 3 were fully vaccinated for their age with PCV13.

Conclusions: Serotype 3 has a preminent role in pneumococcal NP and was associated with all PCV13 vaccination failures. Although in our series the incidence does not seem to be increasing, evolution of pneumococcal NP rates should be monitored after inclusion of PCV13 in the systematic calendar.

© 2020 Sociedad Española de

Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Abbreviations: CI, confidence interval; CT, computed tomography; DNA, deoxyribonucleic acid; IL, interleukin; IPD, invasive pneumococcal disease; PCR, polymerase chain reaction; PCV13, 13-valent pneumococcal conjugate vaccine; RT-PCR, real time polymerase chain reaction; TNF, tumor necrosis factor.

* Corresponding author.

E-mail addresses: sgonzalezperis@gmail.com, segonzalez@vhebron.net (S. González-Peris).

<https://doi.org/10.1016/j.eimc.2020.08.009>

2529-993X/© 2020 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Neumonía necrosante por *Streptococcus pneumoniae* en niños durante el periodo de uso no sistemático de la PCV13 en Cataluña, España

R E S U M E N

Palabras clave:

Neumonía necrosante
Neumonía neumocócica
Vacunas neumocócicas
Streptococcus pneumoniae

Antecedentes: En algunos estudios se ha observado un aumento de la incidencia de neumonía necrosante (NN) en los últimos años. Dicho aumento podría estar asociado a la aparición de serotipos de *S. pneumoniae* no vacunales después de la introducción de la PCV7, aunque se sugiere que factores evolutivos podrían haber modificado la virulencia y las interacciones de los neumococos. El objetivo de este estudio fue definir clínica y microbiológicamente la NN en la población tratada en los 3 hospitales pediátricos principales de Barcelona (Cataluña, España).

Métodos: Se llevó a cabo un estudio observacional prospectivo en pacientes < 18 años hospitalizados a causa de una enfermedad neumocócica invasiva (enero de 2012-junio de 2016). Se recopilaban datos de casos confirmados de NN neumocócica (diagnosticada mediante cultivo o detección de ADN y serotipado). La PCV13 no se administró de forma sistemática en Cataluña durante el periodo del estudio, pero se encontraba disponible en el mercado privado, por lo que la cobertura de vacunación en niños pasó del 48,2 al 74,5%.

Resultados: Se identificaron 35 casos de NN. El 77,1% de los casos estuvieron asociados a un empiema. En los primeros 4 años se observó una tendencia decreciente de la incidencia de NN ($p = 0,021$), especialmente en niños < 5 años ($p = 0,006$). El serotipo 3 causó el 48,6% de los casos. Cinco pacientes con NN debida al serotipo 3 estaban completamente vacunados para su edad con la PCV13.

Conclusiones: El serotipo 3 desempeña un papel prominente en la NN neumocócica y se asoció a todos los fracasos de vacunación de la PCV13. Aunque en nuestra serie la incidencia no parece estar aumentando, debe controlarse la evolución de las tasas de NN neumocócica tras la inclusión de la PCV13 en el calendario sistemático.

© 2020 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Necrotizing pneumonia is a complication of bacterial pneumonia in which areas of necrosis develop within pulmonary condensation. *Streptococcus pneumoniae* is the most frequent etiologic agent in children, but bacteria such as *Staphylococcus aureus*, *Mycoplasma pneumoniae* and *Streptococcus pyogenes*, among others, have also been reported as causal agents.^{1–4} The pathophysiology of necrosis consists of the production of bacterial toxins and vascular changes related to inflammation, including intravascular thrombosis, leading to liquefaction and the subsequent cavitation of the lung parenchyma affected.^{5,6} Recently, an association between the severity of necrosis and bacterial load and high levels of some proinflammatory cytokines (TNF- α , IL-1 β and IL-8) in pleural fluid has been demonstrated.⁷

The clinical course varies in severity, although generally patients show alterations in the health status and prolonged fever in spite of antibiotic treatment. Necrotizing pneumonia is frequently associated with pleural effusion or empyema and may be complicated by respiratory failure and/or sepsis and bronchopleural fistulas.^{8–10} Infrequent late complications such as pneumothorax or tension pneumatocele are reported in patients with residual air cavities.¹¹

Chest X-ray shows radiolucent areas within the consolidated areas that allow necrotizing pneumonia to be suspected, although the frequent association with pleural effusion or dense consolidations may make visualization difficult. Thoracic ultrasound is a very useful complementary examination to confirm the diagnosis and assess vascularity in the area of pneumonia. Occasionally, thoracic computed tomography (CT) may be necessary.

Although necrotizing pneumonia is a relatively infrequent complication, studies have shown an increased incidence in recent years, analogously to cases of pneumonia with pleural effusion or empyema.^{1,8,12,13} This might be related to the emergence of non-vaccine *S. pneumoniae* serotypes after the introduction of the 7-valent vaccine^{3,14} although it is suggested that evolutionary factors may have increased the virulence of pneumococci in their interaction with the host.⁷ The aim of this study was to define,

clinically and microbiologically, necrotizing pneumonia in the population served by three paediatric hospitals in Barcelona (Catalonia, Spain) during a period when the 13-valent pneumococcal conjugate vaccine (PCV13) was already available in the private market but not yet part of the public health system-financed Catalan vaccination calendar. The work also tries to provide the first epidemiological data of necrotizing pneumonia in the PCV13 era.¹⁵

Materials and methods

A prospective observational study of cases of invasive pneumococcal disease (IPD) was carried out in patients aged <18 years admitted to three paediatric hospitals in Barcelona (Hospital de Nens, Hospital Sant Joan de Déu and Vall d'Hebron University Hospital, the last two of them being the largest tertiary paediatric hospitals in Catalonia). The three hospitals represent 31.9% of total paediatric admissions in Catalonia, an autonomous community located in the northeast of Spain. The estimated reference population aged <18 years of these hospitals is 442,761. An active IPD case surveillance protocol was implemented to collect the patients.

The study period was January 2012 to June 2016. PCV13 had been available on the private market since 2010 but was not included in the public health system-financed immunization schedule of Catalonia until July 1, 2016.¹⁶ According to data previously published by our group, the estimated PCV13 vaccination coverage in the reference paediatric population for the three hospitals was 48.2% in 2012, 63.9% in 2013, 68.5% in 2014 and 74.5% in 2015.¹⁷

Information was collected on demographic, epidemiological, clinical and microbiological variables of cases diagnosed, and the vaccination status (verified using vaccination card and/or electronic medical record). Informed consent was obtained in all cases.

Cases of IPD were defined according to the parameters of clinical diagnosis in daily practice in addition to microbiological diagnosis by culture or real-time polymerase chain reaction (PCR) in normally-sterile samples (blood, pleural fluid). The *S. pneumoniae* DNA was detected by RT-PCR, amplifying the pneumolysin (ply),

autolysin (lytA), and wzg (cpsA) genes. Only samples positive for ply/lytA or wzg were included in the study.¹⁸

Strains isolated by culture were serotyped using the Quellung reaction or dot blot by the National Centre for Microbiology, Majadahonda, Madrid, Spain. Culture-negative and PCR-positive samples with a cycle threshold (Ct) >30 cycles were serotyped using a previously-described, real-time multiplex PCR technique.¹⁸ PCR-positive samples with a Ct ≤30 cycles were serotyped using sequential multiplex PCR combined with fragment analysis and automated fluorescent capillary electrophoresis.¹⁹

Pneumococcal necrotizing pneumonia was defined as a clinical entity in which areas of cavitation were observed on imaging studies. In all cases, a paediatric radiologist endorsed the diagnosis of necrotizing pneumonia with the information available in each patient.

Any dose of PCV13 given after six weeks of age, at least four weeks after the previous dose, and at least 15 days before the hospital admission date, was considered valid. According to the PCV13 data sheet,²⁰ we distinguished between unvaccinated patients, completely-vaccinated patients, patients with incomplete but age-appropriate vaccination, and not up-to-date for age vaccinated patients (children who could have received the full age-appropriate regimen but had received an incomplete regimen).

Statistical analysis

The characteristics of necrotizing pneumonia cases were compared with those of other forms of pneumonia. Three groups were distinguished: necrotizing pneumonia, pneumonia with pleural effusion or empyema without signs of necrosis (complicated pneumonia), and uncomplicated bacteremic pneumonia. Quantitative variables were compared using the non-parametric Kruskal–Wallis test. Categorical variables were compared using Pearson's Chi-square test or Fisher's exact test. The incidence of necrotizing pneumonia was calculated for each semester of the study period in all patients and in children aged <5 years. The reference population of both age groups was used as the denominator. The chi-square trend test was used to determine differences in the incidence during the study period. A value of $p < 0.05$ was considered statistically significant. The analysis was performed using the SPSS v24 statistical package and Stata.

Results

Description of the cases

During the study period, 35 cases of necrotizing pneumonia (18%) were identified out of a total of 194 cases of pneumococcal pneumonia. This proportion is higher than that described in other previous studies since not all cases of community-acquired pneumonia are taken into account, but only those cases of pneumonia with microbiological confirmation of pneumococcal aetiology (PCR or culture of pleural fluid or blood).²¹ Table 1 shows the main characteristics of patients with necrotizing pneumonia: 74.3% of patients were aged <5 years. Seven patients (20%) had received home oral antibiotic treatment before hospitalization. No patient had risk factors for IPD or relevant comorbidities: 77.1% of necrotizing pneumonia cases had pleural effusion or empyema. No patient with necrotizing pneumonia was vaccinated against influenza in the season corresponding to the diagnosis.

The time distribution of necrotizing pneumonia cases showed a clear winter predominance, with almost one third of cases occurring in February and 60% in January–March. Fig. 1 shows the evolution of the number of cases of necrotizing pneumonia, complicated pneumonia with effusion or empyema and uncomplicated

Table 1

Characteristics of patients with pneumococcal necrotizing pneumonia.

Clinical form cases (%)		
Necrotizing pneumonia	8 (22.9)	
Necrotizing pneumonia + pleural effusion or empyema	27 (77.1)	
Sex		
Male	20 (57.1)	
Female	15 (42.9)	
Age in months		
Median (range)	40.0 (9–107)	
IQR	25–62	
Birth weight in grams		
Mean (SD)	3140.4 (±0.72)	
Gestational age (weeks)		
Media (SD)	38.0 (± 6.84)	
Diagnostic imaging		
Thoracic ultrasound	17 (48.6)	
Thoracic ultrasound and CT	7 (20.0)	
Thoracic CT	7 (20.0)	
Only chest X-ray	4 (11.4)	
Microbiological diagnostic techniques Positive results (% of those studied):		
PCR in pleural fluid	23 (95.8)	
PCR in blood	17 (81.0)	
Pleural fluid culture	6 (25)	
Blood culture	2 (7.1)	
Streptococcus pneumoniae serotypes		
3	17	(48.6)
1	5	(14.3)
19A	3	(8.6)
7FA	2	(5.7)
14	2	(5.7)
ONV	2	(5.7)
6B	1	(2.9)
6A/C	1	(2.9)
7F	1	(2.9)
12F/A/44/46	1	(2.9)
Vaccination status		
Not vaccinated	21 (60.0)	
Complete vaccination	5 (14.3)	
Not up-to-date for age vaccinated	5 (14.3)	
Vaccination incomplete but age-appropriate	4 (11.4)	
Days from onset symptoms to admission		
Medium (range)	5 (4–7)	
IQR	2–15	
Requirement for thoracentesis/pleural drainage/ECMO		
Thoracentesis with thoracic drainage placement	25 (71.4%)	
Thoracentesis without drainage placement	1 (2.9%)	
ECMO	2 (5.7%)	
Need for surgery		
Thoracoscopy and decortication	4 (11.4)	
Partial or total pneumonectomy	3 (8.6)	
Repair of bronchopleural fistula repair	2 ^a (5.7)	

ONV: other non-vaccine serotypes not specified in serotyping.

ECMO: Extracorporeal membrane oxygenation.

^a In addition to decortication in one patient.

bacteremic pneumonia. Fig. 2 shows necrotizing pneumonia incidence rates for each semester of the study in persons aged <18 years and those aged <5 years. In the first four years of the study, there was a significant decrease (even reaching zero cases in some periods) in necrotizing pneumonia incidence rates, ($p = 0.021$), especially in patients aged <5 years ($p = 0.006$), although there was a rebound in the number of cases in the last six months of the study period.




Fig. 1. Evolution of the number of cases of necrotizing pneumonia, complicated pneumonia with effusion or empyema and uncomplicated bacteremic pneumonia.

Table 2 compares clinical characteristics of cases of necrotizing pneumonia, pneumonia with pleural effusion or empyema without signs of necrosis (complicated pneumonia) and uncomplicated bacteremic pneumonia.

Pleural drainage was required by 71.4% of patients with necrotizing pneumonia during hospitalization. Thoracentesis without drainage placement was made in one patient and 9 patients (25.7%) required surgical intervention (**Table 1**). The most frequent complications were pneumothorax (7 cases, 12.7%) and bronchopleural fistula (5 patients, 9.1%).


Thoracic ultrasound, which is an important imaging test in the diagnosis of necrotizing complications, was performed in 24 cases (68.6%). The PCR for pneumococcus in pleural fluid was the fundamental complementary test for the etiological diagnosis of 23 patients (65.7%), and was positive in 95.8% of patients in whom a pleural fluid sample was obtained, while cultures were positive in only 25% of patients (**Table 1**).

Overall, the characteristics of the cases of necrotizing pneumonia in the series are consistent with data from previous studies, despite some differences in terms of hospital stay and treatment.²²

S. pneumoniae serotypes, vaccination status and vaccine failures

The most frequent serotype was serotype 3, which was identified in 17 cases of necrotizing pneumonia (48.6%), 27 cases of complicated pneumonia (23.3%) and 5 cases of bacteremic pneumonia (11.6%) ($p=0.002$). The association between necrotizing pneumonia and serotype 3 was statistically significant (OR 3.74, 95% CI 1.73–8.07).

Serotype 1 was the second most frequent serotype identified in cases of necrotizing pneumonia (5 cases, 14.3%) but was the most frequent in pneumonia with pleural effusion or empyema without signs of necrosis (36 cases, 31.0%) and was detected in 6 cases of uncomplicated bacteremic pneumonia (14%).



Rate of necrotizing pneumonia per year (per 100,000 persons)	2012-first semester	2012-second semester	2013-first semester	2013-second semester	2014-first semester	2014-second semester	2015-first semester	2015-second semester	2016-first semester
People aged <18 years	1.81	0.23	1.36	0.9	0.9	0	0.45	0.45	1.81
People aged <5 years	6.5	0	3.25	2.44	2.44	0	0.81	0.81	4.87

Fig. 2. Necrotizing pneumonia incidence rates for each semester of the study.

Table 2
Epidemiological and clinical characteristics of types of pneumonia.

	Necrotizing pneumonia (n = 35)	Other complicated pneumonias [non-necrotizing] (n = 116)	Uncomplicated bacteremic pneumonia (n = 43)	p-Value
<i>Age in months</i>				
Median (range)	40.0 (9–107)	44.5 (3–169)	35 (1–193)	0.190
IQR	25–62	24.25–76.25	18–59	
<i>Predisposing disease</i>	No	2 ^a	3 ^b	–
<i>Hospitalization days^a</i>				
Median (range)	13 (5–35) ^c	10 (3–52)	6 (1–61)	<0.001
IQR	10.5–15 ^c	8–13	4–7	
<i>Days of antibiotic therapy (including oral after discharge)^a</i>				
Median (range)	21 (13–42) ^c	16.5 (9–33)	10 (7–45)	<0.001
IQR	16.5–29 ^c	14–20.75	10–12.5	
<i>Need for PICU and length of stay in days^c</i>				
Median (range)	7 (20%)	15 (12.9%)	2 (4.6%)	0.058
IQR	2 (1–33) ^c	4 (1–42)	19 (8–30)	0.186
IQR	1–6 ^c	1–8	–	
<i>Need for mechanical ventilation</i>	6 (17.1%)	3 (2.6%)	–	
<i>Non-invasive ventilation</i>	3 (8.6%)	1 (0.86%)	–	0.005
<i>Invasive ventilation</i>	3 (8.6%)	2 (1.72%)	–	
<i>Complications</i>			–	
Pneumothorax	7 (12.7%)	7 (6.0%)	–	
Bronchopleural fistula	5 (9.1%)	1 (0.9%)	–	–
Lung abscess	1 (1.8%)	–	–	
Other	–	2 ^d	–	
<i>Sequelae at 6 months</i>	3 ^e	3 ^f	–	–
<i>Deaths</i>	0 (0%)	0 (0%)	0 (0%)	–

IQR: interquartile range; ECMO: extracorporeal membrane oxygenation; PICU: pediatric intensive care unit.

^a 1 chronic heart disease and 1 chronic lung disease.

^b 1 medulloblastoma, 1 heart transplant and 1 chronic kidney failure.

^c The case of a 3-year-old patient with septic shock and necrotizing pneumococcal pneumonia who required haemodynamic and respiratory support with ECMO and pneumonectomy with an 11-month paediatric ICU stay excluded from the analysis.

^d 1 patient with haemolytic-uraemic syndrome and 1 with pneumomediastinum.

^e 1 motor deficit secondary to cerebral vascular accident related to ECMO support, 1 pulmonary bulla and 1 patient who required tracheostomy, who developed chronic lung disease and pulmonary hypertension (the patient was treated with ECMO and pneumonectomy).

^f 3 imaging-only sequelae: 2 pleural thickenings and 1 residual impingement of the costophrenic sinus.

Serotypes 3 and 1 were responsible for 22 cases of necrotizing pneumonia (62.9%). The remaining serotypes are shown in Table 2. Data are consistent with previous reports.¹²

PCV13 vaccine serotypes were dominant in both necrotizing pneumonia and complicated pneumonias (85.7% and 79.3%, respectively), and were responsible for 51.4% of cases of bacteremic pneumonia.

Five patients with necrotizing pneumonia were fully vaccinated for their age with PCV13, constituting vaccination failures, all of whom had serotype 3 disease (29.4% of the total of necrotizing pneumonia due to serotype 3).

Table 3 shows the vaccination status of patients with necrotizing pneumonia according to the serotypes involved.

Discussion

This study, carried out between 2012 and 2016, when PCV13 was not included in the public health system-financed vaccination calendar in Catalonia, shows a significant trend to a decrease in the incidence of necrotizing pneumonia due to *S. pneumoniae* (especially in patients aged <5 years) during most of the study period, but a rebound of the disease during the last months of the study. However, the total observation period of the study is relatively short and normal temporal fluctuations should also be taken into account. It's relevant to highlight the central role played by serotype 3 in necrotizing pneumonia. These factors support the need to reinforce epidemiological surveillance.

In part of the literature it is suggested a trend towards more locally-aggressive forms of pneumococcal disease other than occult bacteremia (such as necrotizing pneumonia) after PCV7

vaccination introduction.^{3,23,24} One of the reasons stated is the probable replacement of *S. pneumoniae* serotypes (with the emergence of serotypes such as 3, 19A and 1, among others).^{3,17} Previous results from our same population show that serotype 3 was the most frequent in patients with IPD aged 7–59 months hospitalized in Catalonia in 2012–2016, especially in the 24–59 months age group, which accounted for 75.6% of cases.¹⁷

The preeminent role of serotype 3 as a cause of necrotizing pneumonia and the low effectiveness of PCV13 to prevent this serotype (25.9%; 95% CI: –65.3 to 66.8, according to data published by our group) may partly explain the persistence of the disease.^{17,25–27} In this study, all cases of vaccine failure in necrotizing pneumonia patients were due to serotype 3. Recent studies suggest that PCV13 vaccination may have a greater impact preventing serotype 3 related sepsis and meningitis rather than pneumonia.²⁸

Our results underline the known importance of PCR in pleural fluid, which had a high rate of positivity when it was requested (patients with effusion who were candidates for pleural drainage).^{29,30} PCR in blood also offered a high diagnostic yield. Thoracic ultrasound was the most requested complementary examination for the diagnosis of the necrotizing complication, probably because the technique can provide valuable data at the bedside and without irradiation.

Patients with necrotizing pneumonia required longer hospitalization times, more days of antibiotic administration and, non-significantly, more frequently required intensive care (results are consistent with previously published data³¹). In contrast to other reports,^{1,6,32,33} the proportion of surgical interventions was low, reinforcing the value of conservative approach.^{15,22,34} Overall,

Table 3
PCV13 vaccination status in patients with necrotizing pneumonia by serotype.

Vaccination status	Serotype										Total
	1	3	6B	7F	14	19A	7FA	6A/C	12F/A/44/46	ONV	
Not vaccinated	5	6	0	1	2	2	2	1	0	2	21
Complete vaccination	0	5	0	0	0	0	0	0	0	0	5
Not up-to-date for age vaccinated	0	4	0	0	0	0	0	0	1	0	5
Vaccination incomplete but age-appropriate	0	2	1	0	0	1	0	0	0	0	4
Total	5	17	1	1	2	3	2	1	1	2	35

ONV: other non-vaccine serotypes not specified in serotyping.

patients evolved well and there were no deaths, as other studies report.²²

The study has three major limitations. First, only patients admitted to three hospitals were included; however, these hospitals serve 31.9% of the paediatric population in Catalonia. In addition, the study only included cases in which *S. pneumoniae* was identified in blood or pleural fluid but no other probable cases that were not confirmed microbiologically. Finally, the study period could be relatively short to securely point out a clear trend in a low-incidence disease such as necrotizing pneumonia, as was discussed before.

Conclusions

Pneumococcal necrotizing pneumonia is a serious condition that is often associated with pleural effusion or empyema and which requires prolonged antibiotic therapy and hospitalization.

We found a trend to a decreased incidence of necrotizing pneumonia, whose continuation should be verified. Despite relatively high rates of PCV13 vaccination, serotype 3, which even occurred in fully vaccinated children was the most frequent cause of necrotizing pneumonia and persistence of the disease during the entire study period.

In future years, epidemiological surveillance will be key to monitoring the evolution of IPD in general and pneumococcal necrotizing pneumonia in particular, in order to observe trends after the inclusion of PCV13 in the public health system vaccination schedule. The evolution of disease-causing serotypes is relevant due the association of some serotypes with complicated forms of the disease.

Declarations

All authors have read and approved the manuscript.

Ethics approval and consent to participate

The study has the approval of Sant Joan de Déu Hospital investigation ethics committee.

Consent for publication

We have obtained written informed consent of the patients' parents or guardians.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Funding

This work was supported by the National Plan of R + D + I 2008–2011 and ISCIII Sub-Directorate General for Evaluation and Promotion of Research (Projects PI11/02081 and PI11/2345), and

cofunded by European Regional Development Fund (ERDF) and the Catalan Agency for the Management of Grants for University Research (AGAUR grant number 2014/SGR 1403).

The sources of funding had no role on data collection, analysis, interpretation and writing.

Conflict of interests

Sebastià González-Peris, MD; Fernando Moraga-Llop, MD; Magda Campins, PhD; Àngela Domínguez, PhD; Álvaro Díaz-Conradi, PhD; Mariona F. de Sevilla, PhD; PhD; Sergi Hernández, PhD; Pilar Ciruela, PhD; Gemma Codina, PhD; Sonia Uriona, MD; Núria Soldevila, PhD; Conchita Izquierdo, PhD; Anna Solé-Ribalta, MD; Ana María Planes, PhD; Cristina Esteve, PhD; Johanna Martínez-Osorio, MD and Luis Salleras, PhD, have nothing to disclose.

Juan José García-García, PhD reports grants from Plan Nacional I + D + I, ISCIII - Subdirección General de Educación y Fomento de la Investigación Sanitaria (Project PI 11/02081) and Cofounded by Fondo Europeo de Desarrollo Regional, grants from AGAUR (Grant 2014 SGR 1403), during the conduct of the study; personal fees from Pfizer Inc., outside the submitted work.

Carmen Muñoz-Almagro, PhD reports grants from Instituto de Salud Carlos III, during the conduct of the study; personal fees from GSK Laboratories, grants from Pfizer Laboratories, outside the submitted work.

Acknowledgements

The members of the Barcino Working Group (Projects PI11/02081 and PI11/2345) are: Conchita Izquierdo, Pilar Ciruela, Sergi Hernández (Public Health Agency of Catalonia), Àngela Domínguez, Luis Salleras, Nuria Soldevila (University of Barcelona), Anna Solé-Ribalta, Carmen Muñoz-Almagro, Cristina Esteve, Johanna Martínez-Osorio, Juan José García-García, Mariona F. de Sevilla, (Hospital Sant Joan de Déu Barcelona, University of Barcelona, Barcelona), Ana María Planes, Fernando Moraga-Llop, Gemma Codina, Magda Campins, Sebastià González-Peris, Sonia Uriona, (Vall d'Hebron University Hospital, Barcelona), Alvaro Díaz (Hospital de Nens, Barcelona).

References

1. Sawicki GS, Lu FL, Valim C, Cleveland RH, Colin AA. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. *Eur Respir J.* 2008;31:1285–91.
2. Lemaître C, Angoulvant F, Gabor F, Makhoul J, Bonacorsi S, Naudin J, et al. Necrotizing pneumonia in children. *Pediatr Infect Dis J.* 2013;32:1146–9.
3. Bender JM, Ampofo K, Korgenski K, Daly J, Pavia AT, Mason EO, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? *Clin Infect Dis.* 2008;46:1346–52.
4. Ramphul N, Eastham KM, Freeman R, Eltringham G, Kearns AM, Leeming JP, et al. Cavitary lung disease complicating empyema in children. *Pediatr Pulmonol.* 2006;41:750–3.
5. Hsieh YC, Hsiao CH, Tsao PN, Wang JY, Hsueh PR, Chiang BL, et al. Necrotizing pneumococcal pneumonia in children: the role of pulmonary gangrene. *Pediatr Pulmonol.* 2006;41:623–9.

6. Hacimustafaoglu M, Celebi S, Sarimehmet H, Gurpinar A, Ercan I. Necrotizing pneumonia in children. *Acta Paediatr*. 2004;93:1172–7.
7. Hsieh YC, Chi H, Chang KY, Lai SH, Mu JJ, Wong KS, et al. Increase in fitness of *Streptococcus pneumoniae* is associated with the severity of necrotizing pneumonia. *Pediatr Infect Dis J*. 2015;34:499–505.
8. Hsieh YC, Hsueh PR, Lu CY, Lee PI, Lee CY, Huang LM. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by *Streptococcus pneumoniae* in children in Taiwan. *Clin Infect Dis*. 2004;38:830–5.
9. Krenke K, Sanocki M, Urbankowska E, Kraj G, Krawiec M, Urbankowski T, et al. Necrotizing pneumonia and its complications in children. *Adv Exp Med Biol*. 2015;857:9–17.
10. Hsieh YC, Wang CW, Lai SH, Lai JY, Wong KS, Huang YC, et al. Necrotizing pneumococcal pneumonia with bronchopleural fistula among children in Taiwan. *Pediatr Infect Dis J*. 2011;30:740–4.
11. Demirel N, Quizon A, Beltetón De Leon EL, Reiter J, Colin AA. On the nature of pleural involvement in necrotizing pneumonia: a report of two cases of life threatening late complications. *Pediatr Pulmonol*. 2014;49:E90–5.
12. Silva-Costa C, Brito MJ, Pinho MD, Friães A, Aguiar SI, Ramirez M, et al. Pediatric complicated pneumonia caused by *Streptococcus pneumoniae* serotype 3 in 13-valent pneumococcal conjugate vaccines Portugal, 2010–2015. *Emerg Infect Dis*. 2018;24:1307–14.
13. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. *Pediatr Infect Dis J*. 2006;25:250–4.
14. Kalaskar AS, Heresi GP, Wanger A, Murphy JR, Wootton SH. Severe necrotizing pneumonia in children, Houston, Texas USA. *Emerg Infect Dis*. 2009;15:1696–8.
15. De Benedictis FM, Carloni I. Management of necrotizing pneumonia in children: time for a patient-oriented approach. *Pediatr Pulmonol*. 2019;54:1351–3.
16. Official vaccination schedule of Catalonia: http://canalsalut.gencat.cat/web/contenut/_A-Z/V/vacunacions/documents/calendari.vacunacions.pdf [accessed 19.01.20].
17. Domínguez Á, Ciruela P, Hernández S, García-García JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7–59 months. A matched case-control study. *PLOS ONE*. 2017;12:e0183191.
18. Tarragó D, Fenoll A, Sánchez-Tatay D, Arroyo LA, Muñoz-Almagro C, Esteva C, et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. *Clin Microbiol Infect*. 2008;14:828–34.
19. Selva L, Del Amo E, Brotons P, Muñoz-Almagro C. Rapid and easy identification of capsular serotypes of *Streptococcus pneumoniae* by use of fragment analysis by automated fluorescence-based capillary electrophoresis. *J Clin Microbiol*. 2012;50:3451–7.
20. PCV13 data sheet: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf [accessed 24.08.18].
21. Masters IB, Isles AF, Grimwood K. Necrotizing pneumonia: an emerging problem in children? *Pneumonia (Nathan)*. 2017;9:11.
22. Ehrlichman I, Breuer O, Shoseyov D, Cohen-Cymbereknoh M, Koplewitz B, Averbuch D, et al. Complicated community acquired pneumonia in childhood: different types, clinical course, and outcome. *Pediatr Pulmonol*. 2017;52:247–54.
23. Ricketson LJ, Conradi NG, Vanderkooi OG, Kellner JD. Changes in the nature and severity of invasive pneumococcal disease in children before and after the seven-valent and thirteen-valent pneumococcal conjugate vaccine programs in Calgary, Canada. *Pediatr Infect Dis J*. 2018;37:22–7.
24. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-Valent conjugate vaccine. *Clin Infect Dis*. 2008;46:174–82.
25. Slotved HC, Dalby T, Harboe ZB, Valentiner-Branth P, de Casadevante VF, Espenhain L, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. *Heliyon*. 2016;2:e00198.
26. Syrogiannopoulos GA, Michoula AN, Tsimitselis G, Vassiou K, Chrysanthopoulou DC, Grivea IN. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine. *Infect Dis (Lond)*. 2016;48:749–53.
27. Antachopoulos C, Tsolia MN, Tzanakaki G, Xirogianni A, Dedousi O, Markou G, et al. Parapneumonic pleural effusions caused by *Streptococcus pneumoniae* serotype 3 in children immunized with 13-valent conjugated pneumococcal vaccine. *Pediatr Infect Dis J*. 2014;33:81–3.
28. Lodi L, Ricci S, Nieddu F, Moriondo M, Lippi F, Canessa C, et al. Impact of 13-valent pneumococcal conjugate vaccine on severe invasive disease caused by serotype 3 *Streptococcus pneumoniae* in Italian children. *Vaccines (Basel)*. 2019;7:128.
29. Azzari C, Serranti D, Nieddu F, Moriondo M, Casini A, Lodi L, et al. Significant impact of pneumococcal conjugate vaccination on pediatric parapneumonic effusion: Italy 2006–2018. *Vaccine*. 2019;37:2704–11.
30. Liese JG, Schoen C, van der Linden M, Lehmann L, Goettler D, Keller S, et al. Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010–2017: a nationwide surveillance study. *Clin Microbiol Infect*. 2019;25:857–64.
31. Nicolaou EV, Bartlett AH. Necrotizing pneumonia. *Pediatr Ann*. 2017;46:e65–8.
32. Bolaños-Morales FV, Gómez-Portugal EP, Aguilar-Mena ME, Santillán-Doherty PJ, Sotres-Vega A, Santibáñez-Salgado JA. Lung necrosectomy in pediatric patients with necrotizing pneumonia. *Gen Thorac Cardiovasc Surg*. 2018;66:155–60.
33. Lai JY, Yang W, Ming YC. Surgical management of complicated necrotizing pneumonia in children. *Pediatr Neonatol*. 2017;58:321–7.
34. Gross I, Gordon O, Cohen-Cymbereknoh M, Reiter J, Tsabari R, Gileles-Hillel A, et al. Giant lung cysts following necrotizing pneumonia: resolution with conservative treatment. *Pediatr Pulmonol*. 2019;54:901–6.